Back to Blog

    Notes from the 2026 New Approaches Summit

    October 2, 2026
    Notes from the 2026 New Approaches Summit

    The fifth New Approaches Summit, held at the Harvard Club of New York on September 25, brought together regulators, researchers, manufacturers and investors working on tobacco harm reduction (THR): moving people who smoke onto less harmful sources of nicotine. Pieter Vorster, Hexis's founder and chief executive, gave an address on active engagement and joined the closing panel on misinformation and capital. For us, the most important remarks came from Dr Bret Koplow, recently confirmed as director of the Food and Drug Administration's Center for Tobacco Products (CTP). He expressed a willingness to address two critical issues: misperceptions about relative risk, and a product authorization process so dysfunctional that it has left much of the market for reduced-risk tobacco and nicotine products effectively unregulated.

    The FDA intends to help correct misperceptions

    Dr Koplow set out CTP's four priorities: preventing youth initiation, especially of cigarettes; helping people who smoke to stop, or to switch completely to reduced-risk products; making sure consumers and clinicians have accurate information on relative risks; and removing non-compliant products from the market. All four clearly matter, but the third and fourth seem to us to mark a change of emphasis.

    Dr Koplow called healthcare providers' misunderstanding of nicotine a big missed opportunity, and said he was encouraged by the recent recommendations in the Journal of the American Medical Association (JAMA) that clinicians offer vaping products to patients trying to quit, which we wrote about earlier this month. Those recommendations also highlighted how widespread the problem is: many clinicians, and much of the public, now believe e-cigarettes are as harmful as cigarettes or worse. CTP is expanding its communication on relative risks and testing messages for unintended consequences. "So far it's mostly been me talking about it," he said, "but we're going to be doing things about it."

    A more pragmatic regulator

    Every new nicotine product sold in the US needs FDA marketing authorization, usually through a premarket tobacco product application (PMTA). Dr Koplow said the value of those authorizations is undermined when so much of the market is unauthorized, citing the estimate, also noted in our JAMA post, that nearly 70% of e-cigarette products sold through US grocery and convenience stores were unauthorized at the end of 2025. Building consumer preference for authorized products, he argued, matters as much as the authorizations themselves.

    The fourth priority, removing non-compliant products, connects several of the day's sessions. Lillian Ortega of WOW Solutions explained the FDA's proposed registration and listing rule, which would extend to foreign manufacturers the reporting domestic firms already do, so that the agency can identify products before they reach store shelves. Ao Weinuo, secretary-general of the China Electronics Chamber of Commerce, described a Chinese vape industry regulated since 2022, with stronger enforcement, consolidation and better quality. Together with faster reviews and improved and targeted US enforcement, these changes could eventually move more of the US market back to authorized products.

    Not everyone welcomes the agency's direction. In July the Campaign for Tobacco-Free Kids, the American Academy of Pediatrics, the American Heart Association and others sued the FDA over its May 2026 enforcement guidance, which they say "permits potentially thousands of tobacco products to enter and remain on the market" without authorization.

    Even so, CTP appears willing to be more pragmatic. It cut its backlog of pending applications by about 70% in 2025, and there is no longer a queue at the first stage of review. Reviewers now raise gaps in the data while the scientific review is under way, rather than sending a full list at the end. Dr Koplow appeared willing to consider product standards, which wouldn't remove the need to review each PMTA individually (as the statute requires), but could standardize and simplify the process. Taken together, these steps suggest a regulator willing to work with industry. "We're committed to doing our part," Dr Koplow said, "and I look forward to doing it with you."

    Shifting the focus back to adults who smoke

    Dr Annie Kleykamp of the University of Maryland School of Medicine, one of the authors of the JAMA recommendations, pointed to an imbalance: the Tobacco Control Act, CTP, the loudest lobbying groups and much academic research all focus on youth, and no comparable effort serves older people who smoke. Smoking prevalence among older Americans is broadly stable, so their number is rising as that population grows, and by 2034 Americans over 65 are projected to outnumber those under 18.

    Clinicians could help this group sooner than any change in policy. Dr Edward Anselm of the Icahn School of Medicine at Mount Sinai described how poorly the medical profession performs on cessation, in contrast with diabetes, where it has done a much better job. Low reimbursement is part of the reason; the misperceptions about nicotine that the JAMA recommendations set out to correct are, in our view, another.

    Misinformation reaches investors too

    Our own contribution introduced the key Hexis theme that shareholders can speed the move away from cigarettes by owning companies and pressing their boards for specific, dated commitments, rather than by excluding the sector. We also reported a live poll of US financial professionals on a September 1 webcast: 51% said vaping was about as harmful as smoking or more so, and 7% said it was much less harmful. The misperceptions Dr Koplow described appear to extend to the people who price these companies, so steps by the FDA to improve understanding of relative risk could also improve investors' understanding of the transition, and their interest in it.

    Dr Derek Yach, Chair of the Hexis Harm Reduction Stewardship Council, has also written up his thoughts from the day, noting in particular that the Summit was dedicated to the memory of Scott Ballin, a giant in the field of tobacco and public health: Dialogue Matters: What I Heard at New Approaches 2026

    An investor should consider the investment objectives, risks, and charges and expenses of the fund carefully before investing. A prospectus which contains this and other information about the fund may be obtained by calling 1-800-617-0004, or by clicking here. The prospectus should be read carefully before investing.

    Investing involves risk. Principal loss is possible. The Fund is a recently organized entity, giving prospective investors a limited track record on which to base their investment decision. The Fund’s investments will be concentrated in the securities of issuers in the tobacco, or nicotine-related group of industries. The tobacco industry is subject to significant risks and uncertainties that could materially and adversely affect the financial condition and cash flows, of companies operating in it. Investing in foreign securities typically involves more risks than investing in U.S. securities, and includes risks associated with: (i) internal and external political and economic developments – e.g., the political, economic and social policies and structures of some foreign countries may be less stable and more volatile than those in the U.S. or some foreign countries may be subject to trading restrictions or economic sanctions; (ii) trading practices – e.g., government supervision and regulation of foreign securities and currency markets, trading systems and brokers may be less than in the U.S.; (iii) availability of information – e.g., foreign issuers may not be subject to the same disclosure, accounting and financial reporting standards and practices as U.S. issuers; (iv) limited markets – e.g., the securities of certain foreign issuers may be less liquid (harder to sell) and more volatile; and (v) currency exchange rate fluctuations and policies. Investment in emerging market securities involves greater risk than that associated with investment in securities of issuers in developed foreign countries.

    Derivatives may pose risks in addition to and greater than those associated with investing directly in securities, currencies or other investments, including risks relating to leverage, imperfect correlations with underlying investments or the Fund’s other portfolio holdings, high price volatility, lack of availability, counterparty credit, liquidity, valuation and legal restrictions. A total return swap is a contract in which one party agrees to make periodic payments to another party based on the change in market value of the assets underlying the contract, which may include a specified security, basket of securities, or securities indices during the specified period, in return for periodic payments based on a fixed or variable interest rate or the total return from other underlying assets. The Fund is a non-diversified, investment company under the 1940 Act. Because the Fund is non-diversified, it will invest a greater percentage of its assets in the securities of a limited number of issuers. Investing in medium and small capitalization companies may involve special risks because those companies may have narrower product lines, more limited financial resources, fewer experienced managers, dependence on a few key employees, and a more limited trading market for their stocks, as compared with larger companies. The securities of micro-cap companies may be more volatile in price, have wider spreads between their bid and ask prices, and have significantly lower trading volumes than the securities of larger capitalization companies.

    ETFs are subject to risks that the market price of an ETF's shares may trade at a premium or discount to its net asset value, an active secondary trading market may not develop or be maintained, or trading may be halted by the exchange in which they trade, which may impact an ETF's ability to sell its shares. Shares of any ETF are bought and sold at market price (not NAV) and are not individually redeemed from the ETF. Brokerage commissions will reduce returns.

    The Hexis Nicotine Transition Score (HNTS) is a proprietary framework reflecting the manager’s subjective assessments; independent review by ACA Ethos is not an endorsement of the Fund.

    ETF holdings are subject to change and are not recommendations to buy or sell any security. For current holdings, please click here: Hexis Capital Management | <NICO>

    The Hexis Active Nicotine Engagement ETF is distributed by Quasar Distributors, LLC

    Definitions used on these pages:

    R&D: Research and development spend – investment in developing new products, technologies, or capabilities.

    M&A: Mergers and acquisitions spend – spending on acquiring or merging with other companies to expand scale, capabilities, or market access.

    Capex: Capital expenditure – investment in long-term physical or intangible assets such as facilities, equipment, or infrastructure.

    Discounted Cash Flow (DCF) model – a valuation method that estimates a company’s value by discounting its expected future cash flows back to today.

    Terminal value – the estimated value of a business beyond the explicit forecast period in a DCF model.

    Terminal growth rate – the assumed long-term, steady growth rate used to calculate terminal value.

    EV: Enterprise Value – a measure of a company’s total value, calculated as market capitalisation plus net debt.

    EBITDA: Earnings before interest, taxes, depreciation and amortisation.